Status:
COMPLETED
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
Lead Sponsor:
Benaroya Research Institute
Collaborating Sponsors:
Sanofi
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemot...
Detailed Description
Subjects must have biopsy proven adenocarcinoma of the pancreas which is bidimensionally measurable on CT. Cancer must be considered locally advanced (not able to be treated surgically). Subjects must...
Eligibility Criteria
Inclusion
- Biopsy proven adenocarcinoma of the pancreas
- Tumor must be radiographically bidimensional by abdominal/pelvic CT
- Cancer must be locally advanced and not considered immediately treated by standard surgical procedure
- No prior therapy for pancreas cancer
Exclusion
- Women who are pregnant or lactating
- Subjects who have received prior external beam radiation to the abdomen or pelvis
- Subjects receiving chronic immunosuppressive therapy (prednisone, methotrexate)
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00761241
Start Date
September 1 2008
End Date
April 1 2010
Last Update
May 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Mason Medical Center
Seattle, Washington, United States, 98101